港股異動丨東陽光藥(01558.HK)反彈3.66% 近期多次進行回購操作
格隆匯5月7日丨東陽光藥(01558.HK)自近一年半地位反彈3.66%,報29.75港元,總市值132.2億港元。據格隆匯APP數據顯示,東陽光藥近期多次進行了回購操作,4月29日耗資3784.55萬港元回購128.06萬股,5月4日耗資6415.96萬港元回購221.74萬股,5月5日耗資1369.93萬港元回購47.54萬股。交銀國際發表研究報告表示,公共衞生事件仍在全球範圍內擴散,抗病毒藥物、診斷試劑、醫療設備等領域的大量需求,推動醫藥行業領跑。隨着診斷試劑更多地投入市場,廣譜抗病毒藥物廣泛使用,預計醫藥市場持續向好。抗病毒管線豐富的藥企,目前估值尚並未被充分反映,後續看好擁有多個綜合板塊佈局、研發能力突出、仿製藥領域差異化發展的公司,推薦買入麗珠醫藥及東陽光藥。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.